USO 23133

A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Disease Types: Breast Cancer Research

Eligibility Requirements:

• Men and women with adv/metastatic HR+/HER2- breast cancer
• Pre-/perimenopausal women, men must receive concurrent tx w/ LHRH
agonist
• Pt must have progressed on or w/in 12 months of (neo)adjuvant ET
(single agent or in combo)
• Maximum 1L chemotherapy in metastatic setting
• Measurable disease per RECIST v1.1 or lytic/mixed bone lesion
• Mandatory FFPE tumor sample for central testing
• Mandatory blood samples at screening for central testing
• Previous tx w/ AKT, PI3K, mTOR inhibitors excluded
• Endocrine-based therapy or CDK4/6i in metastatic setting excluded

For more information on this trial CLICK HERE .

Available at:

• Chesapeake
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Williamsburg